Autopsy analysis may contribute to establish actual incidence of second primary malignancies in myeloma

Junichiro Takano, Shotaro Hagiwara, Akiyoshi Miwa
Division of Hematology, Department of Internal Medicine, National Center for Global Health and Medicine, Tokyo, Japan

Abstract

Second primary malignancies (SPMs) are issues for patients with multiple myeloma (MM). There may have been some limitations in prior studies, such as difficulties in a longer follow-up and absence of established screening methods. Therefore, we studied autopsied cases to overcome these limitations. This study aimed to examine SPMs using autopsy reports. Ninety-one cases of MM autopsied at our institution from 1979 to 2013 were analyzed. Median age of autopsied patients was 64.1 years, and proportion of male/female was 59/32. Autopsy was performed in 35.3% of patients died of MM. There were five cases of SPMs with a median confirmation time of 38 (12-132) months from the diagnosis of MM. In three of the five patients, the diagnosis of SPMs was established at autopsy. One case was of myelodysplastic syndrome, and the others were of non-hematological malignancies. The annual risk of SPM estimated using the Kaplan-Meier method was approximately 1%. Three of five SPM cases were detected at autopsy. Analysis of autopsy may contribute to estimate the actual risk of SPMs in MM.

Introduction

In the recent decades, the treatment of multiple myeloma (MM) has markedly improved, however second primary malignancies (SPMs) have become problematic for long-term survivors. The development of SPM in MM may reflect a combination of several causes such as host-related, disease-related, treatment-related, and environmental or behavioral factors. For host factors, MM develops in older populations. A gene expression microarray analysis revealed that germline polymorphisms may play a role in the development of MM and might have some role in the development of SPMs. Among the disease-related factors, epigenetic changes and alterations in signaling pathways may occur with the progression of MM. Furthermore, MM may influence immune cells including macrophages, T cells, or NK cells and disturb tumor immunity. Treatment-related factors have been intensively studied. The tumorigenicity of nitrosourea is a well-known phenomenon. Since Bergsagel et al. observed an increased incidence of acute leukemia with the use of alkylating agents, their role in the development of SPM has been widely assessed. Cuzick et al. reported a positive association between the duration of L-PAM therapy and the subsequent risk of developing leukemia. In addition, they showed the cumulative doses of L-PAM given up to 3 years before the diagnosis of leukemia was the most important risk factor. Although the Finnish Leukemia Group showed no significant correlation between the development of SPM and the use of L-PAM, L-PAM was widely viewed as a risk factor. The risk of SPM after the use of high-dose L-PAM, as a preconditioning regimen for autologous stem cell transplantation, is not considered to increase the risk of SPM compared with lower doses of L-PAM. However, the results of the Intergroupe Fraccophone du Myeloma (IFM) study suggested that the risk may be higher after double transplantation. Recently immunomodulating agents (IMiDs) including thalidomide (Thal) and lenalidomide (Len) were identified as agents that may increase the risk of SPMs; however, this is controversial. For example, a meta-analysis by Palumbo et al. showed that SPMs were linked to Len and L-PAM combination therapy rather than Len monotherapy. The exact mechanism by which SPMs develop remains elusive. Although SPMs in patients with MM have been intensely studied since the 1960s, previous studies have some limitations. For example, they did not follow patients throughout life and the method used to screen for SPMs was not established in earlier studies. Therefore, some SPMs may have been missed. Thus, we studied autopsied cases because an autopsy allows systemic pathological diagnosis and follow-up throughout the entire lifespan of a patient. The aim of this study was to examine SPMs using autopsy reports from patients with MM, although we are aware that focusing only on autopsies may yield some selection bias.

Materials and Methods

As shown in Table 1, this study included 91 consecutive cases of MM autopsied at National Center for Global Health and Medicine, Tokyo, Japan, from 1979 to 2013 (median patient age, 64.1 years; male/female ratio, 59/32). Autopsy was performed in 35.3% of patients died of MM. Most cases were Durie-Salmon stage III (M-proteins IgG/IgA/IgD/BJP/uncertain = 46/12/7/18/8). All patients had undergone conventional treatments. Twenty-one patients also underwent autologous stem cell transplantation (ASCT) during their treatment course. Thal and Len were used in six and three patients, respectively (the duration of Len use was 3-6 months; all three patients underwent ASCT before the administration of Len).

Statistical analysis

The cumulative incidence of SPMs was estimated using the Kaplan-Meier method. Statistical analyses were performed using SPSS (version 17.0).

Results

As shown in Table 2, there were five cases of SPM (5.5% of all cases), with a median confirmation time of 38 (12-132) months since the diagnosis of MM. Prostate (n=2), lungs (n=1), and thyroid (n=1) were the sites of SPMs; there was also one case of myelodysplastic syndrome (MDS). The diagnosis of SPM was established at autopsy in three of the five patients. SPMs tended to develop in older patients with median ages of 68.6 and 62.4 years in patients with or without SPMs, respectively (P=0.300; Table 3). All five patients with SPMs were administered L-PAM, with a median cumulative dose of 784 mg. Three patients also received...
Discussion

SPMs are a potential risk in long-term MM survivors. There have been challenges associated with studies of SPMs in MM, such as insufficient long-term follow-up and absence of an established screening method. The aim of this study was to overcome these limitations using autopsies, which allows the systemic pathological diagnosis and the follow-up of patients’ whole life. We found three cases of SPM that were diagnosed at autopsy. This suggests that studying SPMs using autopsy is feasible. The 5.5% incidence of SPM and the median time of 38 months since the diagnosis of MM observed in the current study are consistent with previous reports. In addition, the annual risk of SPM estimated using the Kaplan-Meier method was similar to data based on 33,229 patients with MM between 1973 and 2008 in the United States, reported by Thomas et al. Among the five cases of SPM, two were prostate cancer. In contrast, Razavi et al. reported a significantly lower overall risk of prostate cancer in patients with MM. The incidence of hematological malignancies in the current study was similar to a recently published report from the Mayo clinic, which reported the long-term follow-up data of newly diagnosed patients with MM treated with Len and dexamethasone. They found that 12 (4.2%) patients had an SPM and only two patients developed hematological malignancies.

Three of the five patients with SPMs were treated with nitrosourea in the current study. All five patients received L-PAM with a median cumulative dose of 784 mg, which is compatible with prior reports. Because of the small number of patients with SPM in the current study, it is difficult to discuss a causal link between the use of IMids or ASCT and the development of SPMs. However, no SPM developed in the three patients who received Len, three of six patients who received Thal developed SPMs, and only one of the 21 patients treated with ASCT later developed an SPM.

The current study has some limitations that must be discussed. First, we could not avoid selection bias because we studied only autopsied cases. Second, the sample size was small. Nevertheless, our data provide several unique insights; especially 3 SPMs were found at autopsy and this may suggest the availability of studying SPMs based on autopsied cases. Because few similar approaches have been previously undertaken, therefore, we recom-

![Figure 1. Cumulative incidence of second primary malignancies estimated using the Kaplan-Meier method.](image)

Table 1. Characteristics of patients.

| Characteristic | N. |
|---------------|----|
| Autopsies in MM patients, % | 35.3 |
| Male/Female | 59/32 |
| Median age at death, years | 64.1 (38-85) |
| Time from diagnosis, months | 49 (1-156) |
| M-protein IgG | 46 |
| IgA | 12 |
| IgD | 7 |
| BJP | 18 |
| Unknown | 8 |
| Durie-Salmon stage | almost all cases are 3 |
| Conventional chemotherapy | 91 |
| ASCT | 21 |
| Thal | 6 |
| Len | 3 |

Table 2. Characteristics of 5 second primary malignancies (SPMs) cases.

| Age | Sex | Time to diagnosis, months | Overall survival, months | SPMs |
|-----|-----|---------------------------|--------------------------|------|
| 1   | 58  | M                         | 38                       | 38   | Prostate |
| 2   | 71  | M                         | 12                       | 14   | Lung     |
| 3   | 75  | M                         | 30                       | 30   | Thyroid  |
| 4   | 64  | M                         | 56                       | 56   | Prostate |
| 5   | 75  | F                         | 21                       | 156  | MDS      |

MDS, myelodysplastic syndrome. Median confirmation time form multiple myeloma diagnosis: 38 (12-132) months. Three SPMs cases are diagnosed at autopsy.

Table 3. Comparison of age and overall survival (OS) between second primary malignancies (SPMs) positive and negative patients.

|             | SPMs positive | SPMs negative | P-value |
|-------------|---------------|---------------|---------|
| Age         | 68.6 years old| 62.7 years old| 0.300   |
| OS          | 38.4 months   | 39 months     | 0.117   |

MM, multiple myeloma; Ig, immunoglobulin; BJP, Bence-Jones protein; ASCT, autologous stem cell transplantation; Thal, thalidomide; Len, lenalidomide.

[Rare Tumors 2015; 7:5949] [page 143]
mend that the current results should be explored in a larger cohort of patients.

References

1. Landgren O, Thomas A, Mailankody, S. Myeloma and second primary cancers. N Engl J Med 2011;365:2241-2.
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60.
3. Knight JA, Skol AD, Shinde A, et al. Myeloma and second primary cancers. N Engl J Med 2011;365:2241-2.
4. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008;113:5575-82.
5. Hideshima T, Mitsiades C, Tonon G, et al. Cytochemistry of multiple myeloma? Leuk Res 2012;36:S3-12.
6. Zhan F , Sawyer J, Tricot G. The role of cytokine genetics in myeloma. Leukemia 2006;20:1484-6.
7. Asimakopoulos F, Jaeypuk K, Ryan A, et al. Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma 2013;54 2112-21.
8. Borello I. Can we change the disease biology of multiple myeloma? Leuk Res 2012;36:53-12.
9. Zeller WJ, Schmähl D. Development of second malignancies in rats after cure of acute leukemia L5222 by single doses of 2-chloroethylnitrosoureas. J Cancer Res Clin Oncol 1979;95:83-6.
10. Bergsagel DE, Bailey AJ, Langley GR, et al. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979;301:743-8.
11. Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukemia following melphalan and cyclophosphamide treatment for myelomatosis: a report to the Medical Research Council’s working party on leukemia in adults. Br J Cancer 1987;55:523-9.
12. Finnish Leukaemia Group. Acute leukemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma. Eur J Haematol 2000;65:123-7.
13. Langdren O, Mailankoby S. Update on second primary malignancies in multiple myeloma: a focused review. Leukemia 2014;28:1423-6.
14. Mailankody S, Pfeiffer RM, Kristinsson S Y, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes following multiple myeloma and its precursor disease (MGUS). Blood 2011;118:4086-92.
15. Attal M, Lauwers-Cances V, Marit G, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1782-91.
16. Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012;119:2764-67.
17. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-69.
18. McCarthy PL, Owzer K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770-81.
19. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014;15:333-42.
20. Guy P. Lenalidomide and second malignancies in myeloma patients. Lancet Oncol 2014;15:253-4.
21. Dong C, Hemminki K. Second primary neoplasms among 53 159 hematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer 2011;85:997-1005.
22. Hasakarl J, Ihorst G, De pasquale D, et al. Association of multiple myeloma with different neoplasms; systemic analysis in consecutive patients with myeloma. Leuk Lymphoma 2011;52:247-59.
23. Razavi P, Rand KA, Cozen W, et al. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J 2013;3:e121.
24. Srivastava G, Rana V, Lacy MQ, et al. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia 2013;27:2062-6.
25. Greene MH, Boice JD, Greer BE, et al. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer. N Engl J Med 1982;1416-21.

Table 4. Treatment history of 5 second primary malignancies (SPMs) cases.

| SPMs     | MCNU | L-PAM, mg | Len | Thal | ASCT | CPM | Other          |
|----------|------|-----------|-----|------|------|-----|----------------|
| 1        | Prostate | No | 370 | No | No | No | No |                |
| 2        | Lung | Yes | 48 | No | No | No | No |                |
| 3        | Thyroid | Yes | unknown | No | No | No | No | VP-16         |
| 4        | Prostate | Yes | 1440 | No | Yes | Yes | 1000 mg | Rx, VAD, BTZ |
| 5        | MDS | No | 1168 | No | Yes | No | No |                |

Median cumulative dose of L-PAM: 784 mg. Thal, thalidomide; Len, lenalidomide; ASCT, Autologous stem cell transplant.